• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Gastrointestinal

The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
  • collapse Eradication of H. pylori or long-term acid suppression in duodenal ulcer disease. MAO Study (metronidazole/ amoxicillin/ omeprazole).A randomized trial with a two-year follow-up.
  • collapse A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with Esomeprazole Magnesium (40 mg qd) to Lansoprazole (30 mg qd) for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis
  • collapse A comparison study of the pharmacodynamic effect of a 40 mg H199/18 MUPS tablet formulation versus a capsule formulation in patients with gastroesophageal reflux symptoms
  • collapse A bioequivalence study with 40 mg H 199/18 comparing a new tablet formulation with a capsule formulation in healthy subjects
  • collapse A bioequivalence study with 20 mg H 199/18 comparing a new tablet formulation with a capsule formulation in healthy subjects
  • collapse A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d.
  • collapse A randomised double-blind placebo-controlled multi-centre pilot study to assess symptom response in subjects with pain or discomfort in the chest receiving oral treatment with esomeprazole 40 mg bid for 4 weeks
  • collapse A randomised, double-blind, multicentre dose-finding Phase IIb study for up to 8 weeks¿ treatment with AZD0865 25, 50, 75 mg and esomeprazole 40 mg, given orally once daily for the healing of erosive esophagitis in adult subjects with GERD with erosive esophagitis according to the LA classification in adult subjects
  • collapse A 4-week, randomised, double-blind, multicentre, dose-finding Phase IIb study with AZD0865 25, 50, 75 mg and esomeprazole 20 mg, given orally once daily for the treatment of GERD without erosive esophagitis according to the LA classification in adult subjects
  • collapse A single-centre, open, randomised, three-way cross-over drug-drug interaction study of D961H capsule and loxoprofen tablet after repeated oral administration in Japanese healthy male subjects
  • Pages
  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013